Print Page | Close Window

"Anti Science" is a propaganda ploy

Printed From: Avian Flu Talk
Category: Main Forums
Forum Name: General Discussion
Forum Description: (General discussion regarding the next pandemic)
URL: http://www.avianflutalk.com/forum_posts.asp?TID=44620
Printed Date: April 17 2024 at 8:08pm


Topic: "Anti Science" is a propaganda ploy
Posted By: A-I
Subject: "Anti Science" is a propaganda ploy
Date Posted: January 07 2022 at 1:32pm

I'm not one to really care or pay attention to what celebrities say or what their opinions are. Generally their opinions carry no more weight for me than that of anyone else and rightly so. That being said every now and again one says something that is relevant and it catches my attention. Aaron Rodgers statement ""If science can't be questioned, it's not science anymore; it's propaganda and that's the truth,"  last week is one of those.

Information/science/studies relevant to the vaxx and it's safety as well as it effects and efficacy are hardly propaganda they are merely expanding the information available based on scientific data as it is studied and becomes available. To say "they" know everything to know about the vaxx is not true and inaccurate, as that information and data is expanding daily. 

The relevance to that information as it relates to each and everyone of us is to enable each of us to make an informed decision as an individual as to if the vaxx is right for you. The decision making process for most begins with looking at the information, and weighing that information both the positives and negatives and formulating and enacting a plan of action. Some do not go that route, instead relying on others to make their decisions for them. And that route is not just pertinent to the vaxx situation but rather other aspects of life as well, it's just how some are built they will accept whatever the government/media talking heads say without question. Despite history showing that is indeed a bad route to follow.

The difference I see is that people who oppose the vaxx for whatever reason and it's mandates or compulsory use are not demanding that people who choose to be vaxxed stop taking or are denied the vaxx. The opposite can not be said for a significant segment of the pro vaxx group. That is a marked difference. And that is where the propaganda ploy of "anti science" begins.

Science changes based on the data. If it didn't the world would still be flat, cigarettes would still be healthy for you and DDT would still be considered a miracle. 

Bottom line: I'm not making your choices, you sure as hell won't be making mine and you won't be using "anti science" as a propaganda tool. Everyone makes their own informed decisions.

So without further delay on to the science to enable an informed decision.

Over 1100 scientific studies and/or reports on the dangers associated with COVID injections related to blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis, Bell’s palsy, Guillain-Barre, deaths, etc.

Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicenter cohort study:  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/fulltext" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/fulltext 2.

Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S1052305721003414" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1052305721003414 3.

  1. Fatal cerebral hemorrhage after COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33928772/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33928772/
  2. Myocarditis after mRNA vaccination against SARS-CoV-2, a case series:  https://www.sciencedirect.com/science/article/pii/S2666602221000409" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2666602221000409
  3. Three cases of acute venous thromboembolism in women after vaccination against COVID-19:  https://www.sciencedirect.com/science/article/pii/S2213333X21003929" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2213333X21003929
  4. Acute thrombosis of the coronary tree after vaccination against COVID-19:  https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988
  5. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020:  https://pubmed.ncbi.nlm.nih.gov/33929487/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33929487/
  6. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine:  https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/fullte" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/fullte xt
  7. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET):  https://pubmed.ncbi.nlm.nih.gov/33871350/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33871350/
  8. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review:  https://www.sciencedirect.com/science/article/pii/S0022510X21003014" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0022510X21003014
  9. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:  https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381
  10. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma:  https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505
  11. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines:  https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904
  12. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis:  https://www.sciencedirect.com/science/article/pii/S1665268121000557" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1665268121000557
  13. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid):  https://www.sciencedirect.com/science/article/pii/S1050173821000967" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1050173821000967
  14. Roots of autoimmunity of thrombotic events after COVID-19 vaccination:  https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160
  15. Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience:  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext
  16. Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine:  https://www.nejm.org/doi/full/10.1056/nejme2106315" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/nejme2106315

Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601

  1. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article
  2. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children:  https://pubmed.ncbi.nlm.nih.gov/34374740/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34374740/
  3. Myocarditis and pericarditis after covid-19 vaccination:  https://jamanetwork.com/journals/jama/fullarticle/2782900?fbclid=IwAR06pFKNF" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jama/fullarticle/2782900?fbclid=IwAR06pFKNF Mfx7N6RbPK6bYUZ1y8xPnnCK9K5iZYlcEzhX8t68syO5JBwp3w
  4. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19:  https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article
  1. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19):  https://haematologica.org/article/view/haematol.2021.279075" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://haematologica.org/article/view/haematol.2021.279075
  2. Pathological antibodies against platelet factor 4 after vaccination with ChAdOx1 nCoV-19. This article states: “In the absence of previous prothrombotic medical conditions, 22 patients had acute thrombocytopenia and thrombosis, mainly cerebral venous thrombosis, and 1 patient had isolated thrombocytopenia and a hemorrhagic phenotype”:  https://www.nejm.org/doi/full/10.1056/NEJMoa2105385?query=TOC&fbclid=IwA" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMoa2105385?query=TOC&fbclid=IwA R2ifm2TQjetAMb42YRRUlKEeqCQe-lDasIWvjMgzHHaItbuPbu6n7NlG3cic.
  3. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):  https://www.sciencedirect.com/science/article/pii/S0264410X21005247" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0264410X21005247
  4. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination:  https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478
  5. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man.  https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005
  6. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines:  https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895
  7. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination:  https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315
  8. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data:  https://www.sciencedirect.com/science/article/pii/S0896841121000937" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0896841121000937
  9. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine:  https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098
  10. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT):  https://www.sciencedirect.com/science/article/pii/S0953620521002363" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0953620521002363
  11. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers:  https://www.sciencedirect.com/science/article/pii/S0828282X21006243" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0828282X21006243
  12. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”:  https://www.sciencedirect.com/science/article/pii/S2666572721000389" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2666572721000389
  13. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S:  https://www.sciencedirect.com/science/article/pii/S0196064421003425" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0196064421003425
  14. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S1443950621011562" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1443950621011562
  15. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection:  https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706
  16. Prothrombotic immune thrombocytopenia after COVID-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S0006497121009411" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0006497121009411
  17. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story:  https://www.sciencedirect.com/science/article/pii/S2589936821000256" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2589936821000256
  18. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation:  https://www.sciencedirect.com/science/article/pii/S1871402121002046" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1871402121002046
  19. Thrombosis after COVID-19 vaccination: possible link to ACE pathways:  https://www.sciencedirect.com/science/article/pii/S0049384821004369" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0049384821004369
  20. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19:  https://www.sciencedirect.com/science/article/pii/S0735109721051949" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0735109721051949
  21. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S0735675721005714" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0735675721005714
  22. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom:  https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
  1. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19):  https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963 .
  2. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?:  https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ
  3. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?:  https://www.sciencedirect.com/science/article/pii/S0953620521002314" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0953620521002314
  4. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S0213485321000839" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0213485321000839
  5. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”:  https://pubmed.ncbi.nlm.nih.gov/33918932/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33918932/





-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.


Replies:
Posted By: A-I
Date Posted: January 07 2022 at 1:34pm
  1. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”:  https://pubmed.ncbi.nlm.nih.gov/33918932/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33918932/
  2. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33606296/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33606296/
  3. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33854395/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33854395/
  4. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
  5. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase:  https://pubmed.ncbi.nlm.nih.gov/33863748/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33863748/
  6. Cerebral venous thrombosis associated with the covid-19 vaccine in Germany:  https://onlinelibrary.wiley.com/doi/10.1002/ana.26172" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
  7. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event:  https://pubmed.ncbi.nlm.nih.gov/34133027/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34133027/
  8. The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34001390/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34001390/
  9. Thrombosis with thrombocytopenia after messenger RNA vaccine -1273:  https://pubmed.ncbi.nlm.nih.gov/34181446/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34181446/
  10. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data:  https://pubmed.ncbi.nlm.nih.gov/34174723/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34174723/
  11. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland:  https://www.nature.com/articles/s41591-021-01408-4" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nature.com/articles/s41591-021-01408-4
  12. Exacerbation of immune thrombocytopenia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34075578/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34075578/
  13. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34105244/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34105244/
  14. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia:  https://www.nejm.org/doi/full/10.1056/NEJMc2106383" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMc2106383
  15. Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia:  https://www.nature.com/articles/s41586-021-03744-4" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nature.com/articles/s41586-021-03744-4
  16. Frequency of positive anti-PF4 antibody/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2:  https://ashpublications.org/blood/article-abstract/138/4/299/475972/Frequency-of-p" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://ashpublications.org/blood/article-abstract/138/4/299/475972/Frequency-of-p ositive-anti-PF4-polyanion-antibody?redirectedFrom=fulltext
  17. Myocarditis with COVID-19 mRNA vaccines:  https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135
  18. Myocarditis and pericarditis after COVID-19 vaccination:  https://jamanetwork.com/journals/jama/fullarticle/2782900" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jama/fullarticle/2782900
  19. Myocarditis temporally associated with COVID-19 vaccination:  https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891 .
  20. COVID-19 Vaccination Associated with Myocarditis in Adolescents:  https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf
  21. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:  https://pubmed.ncbi.nlm.nih.gov/33994339/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33994339/
  22. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature:  https://www.sciencedirect.com/science/article/pii/S1553838921005789" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1553838921005789
  23. COVID-19 vaccine-induced myocarditis: a case report with review of the literature:  https://www.sciencedirect.com/science/article/pii/S1871402121002253" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1871402121002253
  24. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings:  https://www.sciencedirect.com/science/article/pii/S1936878X2100485X" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1936878X2100485X
  25. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent:  https://www.sciencedirect.com/science/article/pii/S002234762100617X" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S002234762100617X
  1. Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients:  https://www.sciencedirect.com/science/article/pii/S0167527321012286" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0167527321012286 .
  2. Acute myocarditis after administration of BNT162b2 vaccine:  https://www.sciencedirect.com/science/article/pii/S2214250921001530" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2214250921001530
  3. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector:  https://www.sciencedirect.com/science/article/pii/S2352906721001573" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2352906721001573
  4. Myocarditis following vaccination with BNT162b2 in a healthy male:  https://www.sciencedirect.com/science/article/pii/S0735675721005362" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0735675721005362
  5. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection:  https://www.sciencedirect.com/science/article/pii/S1930043321005549" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1930043321005549
  6. Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents:  https://www.sciencedirect.com/science/article/pii/S002234762100665X" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S002234762100665X
  7. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine:  https://www.sciencedirect.com/science/article/pii/S1885585721002218" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1885585721002218
  8. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA:  https://www.sciencedirect.com/science/article/pii/S2589790X21001931" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2589790X21001931
  9. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection:  https://www.sciencedirect.com/science/article/pii/S2352906721000622" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2352906721000622
  10. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age:  https://www.sciencedirect.com/science/article/pii/S0022347621007368" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0022347621007368
  11. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man:  https://www.sciencedirect.com/science/article/pii/S0870255121003243" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0870255121003243
  12. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents:  https://www.sciencedirect.com/science/article/pii/S0022347621007496" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0022347621007496
  13. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2:  https://www.sciencedirect.com/science/article/pii/S1936878X21004861" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1936878X21004861
  14. Takotsubo cardiomyopathy after vaccination with mRNA COVID-19:  https://www.sciencedirect.com/science/article/pii/S1443950621011331" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1443950621011331
  15. COVID-19 mRNA vaccination and myocarditis:  https://pubmed.ncbi.nlm.nih.gov/34268277/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34268277/
  16. COVID-19 vaccine and myocarditis:  https://pubmed.ncbi.nlm.nih.gov/34399967/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34399967/
  17. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study  https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706.
  18. COVID-19 vaccines and myocarditis:  https://pubmed.ncbi.nlm.nih.gov/34246566/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34246566/
  19. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines  https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; - https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp lications-of-the-mrna-based-covid-19-vaccines  https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp lications-of-the-mrna-based-covid-19-vaccines
  20. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34340927/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34340927/
  21. Myocarditis with covid-19 mRNA vaccines:  https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135
  22. Association of myocarditis with COVID-19 mRNA vaccine in children:  https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co vid-19-vaccine-in-children/
  23. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
  24. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C
  25. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
  26. Myocarditis following immunization with Covid-19 mRNA:  https://www.nejm.org/doi/full/10.1056/NEJMc2109975" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMc2109975


-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:35pm
  1. Myocarditis following immunization with Covid-19 mRNA:  https://www.nejm.org/doi/full/10.1056/NEJMc2109975" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMc2109975
  2. Patients with acute myocarditis after vaccination withCOVID-19 mRNA:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
  3. Myocarditis associated with vaccination with COVID-19 mRNA:  https://pubs.rsna.org/doi/10.1148/radiol.2021211430" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubs.rsna.org/doi/10.1148/radiol.2021211430

Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination:  https://pediatrics.aappublications.org/content/148/3/e2021052478" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pediatrics.aappublications.org/content/148/3/e2021052478

  1. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series:  https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4

Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA:  https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocar" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocar ditis-and-pericarditis

  1. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA:  https://pubmed.ncbi.nlm.nih.gov/34402228/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402228/
  2. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine:  https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
  3. Myocarditis / pericarditis associated with COVID-19 vaccine:  https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
  4. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine:  https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx
  5. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine:  https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543
  6. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism:  https://pubmed.ncbi.nlm.nih.gov/34312010/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34312010/
  7. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database:  https://pubmed.ncbi.nlm.nih.gov/34219532/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34219532/
  8. Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination:  https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033
  9. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings:  https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236
  10. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine:  https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038
  11. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?:  https://pubmed.ncbi.nlm.nih.gov/34333695/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34333695/

Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/

  1. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?:  https://pubmed.ncbi.nlm.nih.gov/34118375/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34118375/
  2. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34180390/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34180390/
  3. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report:  https://pubmed.ncbi.nlm.nih.gov/34133825/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34133825/
  4. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report:  https://pubmed.ncbi.nlm.nih.gov/34487236/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34487236/
  5. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis?

a.  https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059

  1. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34447639/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34447639/
  2. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report:  https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183
  3. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship:  https://pubmed.ncbi.nlm.nih.gov/34236331/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34236331/
  4. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34435250/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34435250/
  5. COVID-19 vaccine-induced rhabdomyolysis: case report with literature review:  https://pubmed.ncbi.nlm.nih.gov/34186348/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34186348/ .
  6. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development:  https://www.sciencedirect.com/science/article/pii/S2666354621000065" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2666354621000065

Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association:  https://www.sciencedirect.com/science/article/pii/S0303846721004169" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0303846721004169

  1. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature:  https://www.sciencedirect.com/science/article/pii/S0165572821002186" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0165572821002186

Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association:  https://www.sciencedirect.com/science/article/pii/S2214250921000998" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2214250921000998 .

  1. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report:  https://www.sciencedirect.com/science/article/pii/S0736467921006442" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0736467921006442

Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report:  https://www.sciencedirect.com/science/article/pii/S0035378721005853" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0035378721005853 .

  1. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination:  https://www.sciencedirect.com/science/article/pii/S2049080121005343" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2049080121005343
  2. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report:  https://www.sciencedirect.com/science/article/pii/S2049080121007536" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2049080121007536
  3. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database:  https://www.sciencedirect.com/science/article/pii/S1201971221007049" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1201971221007049
  4. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence:  https://www.sciencedirect.com/science/article/pii/S0899707121003557" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0899707121003557 .
  5. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S0165572821001569" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0165572821001569
  6. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association:  https://www.sciencedirect.com/science/article/pii/S0165572821002137" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0165572821002137
  7. Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story:  https://www.sciencedirect.com/science/article/pii/S1473309921002735" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1473309921002735
  8. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: bhttps://www.sciencedirect.com/science/article/pii/S266635462100020X
  9. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:.  https://www.sciencedirect.com/science/article/pii/S2451993621001456" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2451993621001456 .
  10. Bell’s palsy after COVID-19 vaccination: case report:  https://www.sciencedirect.com/science/article/pii/S217358082100122X" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S217358082100122X .
  11. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history:  https://www.sciencedirect.com/science/article/pii/S2213219821007972" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2213219821007972
  12. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET:  https://www.sciencedirect.com/science/article/pii/S1930043321002612" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1930043321002612
  13. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:  https://www.sciencedirect.com/science/article/pii/S0272638621007423" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0272638621007423
  14. Late cutaneous reactions after administration of COVID-19 mRNA vaccines:  https://www.sciencedirect.com/science/article/pii/S2213219821007996" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2213219821007996
  15. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature:  https://www.sciencedirect.com/science/article/pii/S1871402121001880" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1871402121001880
  16. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study:  https://www.sciencedirect.com/science/article/pii/S0190962221024427" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0190962221024427
  17. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:.  https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381 .


-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:37pm
  1. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:.  https://www.sciencedirect.com/science/article/pii/S1939455121000119" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1939455121000119 .
  2. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:.  https://www.sciencedirect.com/science/article/pii/S1871402121002046" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1871402121002046 .
  3. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:.  https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X
  4. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:.  https://www.sciencedirect.com/science/article/pii/S0896841121000937" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0896841121000937 .
  5. immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:.  https://www.sciencedirect.com/science/article/pii/S2214250921002018" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2214250921002018 .
  6. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report:  https://www.sciencedirect.com/science/article/pii/S1876034121001878" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1876034121001878 .
  1. COVID-19 RNA-based vaccines and the risk of prion disease:  https://scivisionpub.com/pdfs/covid19-rna-based-vaccines-and-the-risk-of-prion-dis" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://scivisionpub.com/pdfs/covid19-rna-based-vaccines-and-the-risk-of-prion-dis ease-1503.pdf
  2. This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines:  https://www.nejm.org/doi/full/10.1056/NEJMoa2104983" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMoa2104983 .
  3. Process-related impurities in the ChAdOx1 nCov-19 vaccine:  https://www.researchsquare.com/article/rs-477964/v1" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.researchsquare.com/article/rs-477964/v1
  4. COVID-19 mRNA vaccine causing CNS inflammation: a case series:  https://link.springer.com/article/10.1007/s00415-021-10780-7" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://link.springer.com/article/10.1007/s00415-021-10780-7
  5. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33475702/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33475702/
  6. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol:  https://pubmed.ncbi.nlm.nih.gov/33320974/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33320974/
  7. Pfizer Vaccine Raises Allergy Concerns:  https://pubmed.ncbi.nlm.nih.gov/33384356/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33384356/
  8. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020:  https://pubmed.ncbi.nlm.nih.gov/33444297/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33444297/

Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021:  https://pubmed.ncbi.nlm.nih.gov/33507892/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33507892/

  1. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021:  https://pubmed.ncbi.nlm.nih.gov/34414880/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34414880/
  2. reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021:  https://pubmed.ncbi.nlm.nih.gov/33576785/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33576785/
  3. Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data:  https://pubmed.ncbi.nlm.nih.gov/34269740/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34269740/
  4. Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34215453/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34215453/
  5. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research:  https://pubmed.ncbi.nlm.nih.gov/33932618/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33932618/
  6. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA):  https://pubmed.ncbi.nlm.nih.gov/33643776/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33643776/
  7. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines:  https://pubmed.ncbi.nlm.nih.gov/33571463/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33571463/
  8. Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown:  https://pubmed.ncbi.nlm.nih.gov/33527524/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33527524/
  9. Cutaneous adverse effects of available COVID-19 vaccines:  https://pubmed.ncbi.nlm.nih.gov/34518015/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34518015/
  10. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report:  https://pubmed.ncbi.nlm.nih.gov/34347278/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34347278/
  11. COVID-19 vaccines increase the risk of anaphylaxis:  https://pubmed.ncbi.nlm.nih.gov/33685103/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33685103/
  12. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34050949/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34050949/
  13. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation:  https://pubmed.ncbi.nlm.nih.gov/33657648/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33657648/
  14. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33825239/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33825239/
  15. Acute allergic reactions to COVID-19 mRNA vaccines:  https://pubmed.ncbi.nlm.nih.gov/33683290/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33683290/
  16. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2:  https://pubmed.ncbi.nlm.nih.gov/33919151/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33919151/
  17. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data:  https://pubmed.ncbi.nlm.nih.gov/34128049/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34128049/

Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience:  https://pubmed.ncbi.nlm.nih.gov/34474708/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34474708/

Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI):  https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447?journalCod" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447?journalCod e=yacb20.

  1. IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines:  https://pubmed.ncbi.nlm.nih.gov/34318537/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34318537/

Allergic reactions after COVID-19 vaccination: putting the risk in perspective:  https://pubmed.ncbi.nlm.nih.gov/34463751/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34463751/

Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies:  https://pubmed.ncbi.nlm.nih.gov/33846043/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.

  1. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts:  https://pubmed.ncbi.nlm.nih.gov/33752263/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33752263/
  2. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis:  https://pubmed.ncbi.nlm.nih.gov/34073536/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34073536/
  3. Fatal brain hemorrhage after COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33928772/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33928772/
  4. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University:  https://pubmed.ncbi.nlm.nih.gov/34423106/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34423106/
  5. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases:  https://pubmed.ncbi.nlm.nih.gov/33838206/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33838206/
  6. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study:  https://pubmed.ncbi.nlm.nih.gov/34517079/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34517079/

Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases:  https://pubmed.ncbi.nlm.nih.gov/34254291/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34254291/

Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry:  https://pubmed.ncbi.nlm.nih.gov/34487581/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34487581/

  1. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome:  https://pubmed.ncbi.nlm.nih.gov/33987882/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33987882/
  2. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34138513/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34138513/
  3. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea:  https://pubmed.ncbi.nlm.nih.gov/34402235/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402235/
  4. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study:  https://pubmed.ncbi.nlm.nih.gov/34446426/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34446426/

Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review:  https://pubmed.ncbi.nlm.nih.gov/34365148/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34365148/ .



-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:38pm
  1. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials:  https://pubmed.ncbi.nlm.nih.gov/34452064/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34452064/ .
  2. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33917902/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33917902/
  3. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT):  https://pubmed.ncbi.nlm.nih.gov/34256983/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34256983/

Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34247246/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34247246/ .

  1. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34132839/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34132839/
  2. 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34117206/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34117206/
  3. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.

a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience:  https://pubmed.ncbi.nlm.nih.gov/34033927/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34033927/

  1. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines:  https://pubmed.ncbi.nlm.nih.gov/34277198/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34277198/
  2. Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34364831/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34364831/
  3. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern:  https://pubmed.ncbi.nlm.nih.gov/34447639/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34447639/
  4. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273:  https://pubmed.ncbi.nlm.nih.gov/34514306/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34514306/
  1. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/33946748/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33946748/
  2. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis:  https://pubmed.ncbi.nlm.nih.gov/34453510/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34453510/
  3. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33476455/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33476455/
  4. propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34451967/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34451967/
  5. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34377889/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34377889/
  6. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia:  https://pubmed.ncbi.nlm.nih.gov/34272095/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34272095/
  7. COVID-19 vaccination association and facial nerve palsy: A case-control study:  https://pubmed.ncbi.nlm.nih.gov/34165512/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34165512/
  8. The association between COVID-19 vaccination and Bell’s palsy:  https://pubmed.ncbi.nlm.nih.gov/34411533/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34411533/

Bell’s palsy after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33611630/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33611630/

Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222):  https://pubmed.ncbi.nlm.nih.gov/33981305/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33981305/

  1. Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34336436/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34336436/
  2. Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34281950/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34281950/ .
  3. Transverse myelitis induced by SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34458035/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34458035/
  4. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19):  https://pubmed.ncbi.nlm.nih.gov/33734623/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33734623/
  5. Acute abducens nerve palsy after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34044114/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34044114/ .
  6. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database:  https://pubmed.ncbi.nlm.nih.gov/34492394/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34492394/
  7. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34369471/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34369471/
  8. Bell’s palsy after Ad26.COV2.S COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34014316/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34014316/
  9. Bell’s palsy after COVID-19 vaccination: case report:  https://pubmed.ncbi.nlm.nih.gov/34330676/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34330676/
  10. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34272622/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34272622/
  11. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34477091/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34477091/
  12. Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33975372/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33975372/ .
  13. Bell’s palsy after COVID-19 vaccination with high antibody response in CSF:  https://pubmed.ncbi.nlm.nih.gov/34322761/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34322761/ .
  14. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519:  https://pubmed.ncbi.nlm.nih.gov/34139321/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34139321/ .
  15. Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report:  https://pubmed.ncbi.nlm.nih.gov/34032902/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34032902/ .
  16. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?:  https://pubmed.ncbi.nlm.nih.gov/33862041/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33862041/
  17. Autoimmune hepatitis triggered by vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/34332438/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34332438/
  18. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity:  https://pubmed.ncbi.nlm.nih.gov/34293683/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34293683/ .
  19. Autoimmune hepatitis after COVID vaccine:  https://pubmed.ncbi.nlm.nih.gov/34225251/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34225251/
  20. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34449715/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34449715/
  1. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines:  https://pubmed.ncbi.nlm.nih.gov/34139631/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34139631/ .
  2. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/33864750/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33864750/
  3. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/33914590/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33914590/
  4. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19:  https://pubmed.ncbi.nlm.nih.gov/34420802/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34420802/
  5. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency:  https://pubmed.ncbi.nlm.nih.gov/34293217/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34293217/
  6. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study:  https://pubmed.ncbi.nlm.nih.gov/34446426/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34446426/
  7. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data:  https://pubmed.ncbi.nlm.nih.gov/34174723/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34174723/
  8. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study:  https://pubmed.ncbi.nlm.nih.gov/33952445/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33952445/
  9. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland:  https://pubmed.ncbi.nlm.nih.gov/34108714/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34108714/
  10. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany:  https://pubmed.ncbi.nlm.nih.gov/34288044/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34288044/
  11. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34341358/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34341358/
  12. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence:  https://pubmed.ncbi.nlm.nih.gov/34261633/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34261633/ .
  13. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34256983/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34256983/
  14. Thrombocytopenia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34332437/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34332437/ .
  15. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33845870/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33845870/ .
  16. Thrombosis with thrombocytopenia syndrome after COVID-19 immunization:  https://pubmed.ncbi.nlm.nih.gov/34236343/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34236343/
  17. Acute myocardial infarction within 24 hours after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34364657/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34364657/ .
  18. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34287612/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34287612/
  19. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental:  https://pubmed.ncbi.nlm.nih.gov/34478433/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34478433/
  20. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea:  https://pubmed.ncbi.nlm.nih.gov/34402235/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402235/
  21. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation:  https://pubmed.ncbi.nlm.nih.gov/34186376/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34186376/ 263.
  22. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34101024/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34101024/
  23. A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/34137813/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34137813/

Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines:  https://pubmed.ncbi.nlm.nih.gov/34191218/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34191218/ 266.

  1. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy:  https://pubmed.ncbi.nlm.nih.gov/34175640/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34175640/
  2. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34153802/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34153802/
  3. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines:  https://pubmed.ncbi.nlm.nih.gov/34092488/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34092488/
  4. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34261635/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34261635/
  1. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34132839/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34132839/ .
  2. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34144250/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34144250/
  3. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/33687691/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33687691/
  4. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34011137/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34011137/ .
  5. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series:  https://pubmed.ncbi.nlm.nih.gov/34393988/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34393988/ .
  6. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34129181/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34129181/ .

Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers:  https://pubmed.ncbi.nlm.nih.gov/34083026/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34083026/ .

  1. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34247246/ .
  2. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal hemorrhage: https://pubmed.ncbi.nlm.nih.gov/34235757/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34235757/ .
  3. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34473841/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34473841/ .
  4. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34189756/
  5. Cerebral venous thrombosis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34045111/ .
  6. Lipschütz ulcers after AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34366434/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34366434/ .
  7. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: https://pubmed.ncbi.nlm.nih.gov/34330677/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34330677/
  8. Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34181446/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34181446/
  9. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34477089/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34477089/
  10. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34071883/
  11. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34033367/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34033367/
  12. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: https://pubmed.ncbi.nlm.nih.gov/34375510/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34375510/
  13. Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34107198/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34107198/
  14. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34355379/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34355379/ .
  15. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: https://pubmed.ncbi.nlm.nih.gov/34452028/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34452028/
  16. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34202817/
  17. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34237213/ .
  18. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34105247/ .
  19. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34405870/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34405870/ .
  20. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34416410/ .
  21. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34462013/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34462013/ .
  22. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34224024/ .
  23. Post-vaccinal encephalitis after ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34324214/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34324214/

Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34507266/



-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:39pm
  1. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma:  https://pubmed.ncbi.nlm.nih.gov/34459725/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34459725/
  2. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19:  https://pubmed.ncbi.nlm.nih.gov/34463066/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34463066/
  3. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome:  https://pubmed.ncbi.nlm.nih.gov/34043800/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34043800/ .
  4. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine:  https://pubmed.ncbi.nlm.nih.gov/34447646/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34447646/
  5. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study:  https://pubmed.ncbi.nlm.nih.gov/34479760/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34479760/ .
  6. fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients:  https://pubmed.ncbi.nlm.nih.gov/34416319/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34416319/ .
  7. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST):  https://pubmed.ncbi.nlm.nih.gov/34092166/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34092166/
  8. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34291477/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34291477/
  9. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34513435/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34513435/
  10. Hepatitis C virus reactivation after COVID-19 vaccination: a case report:  https://pubmed.ncbi.nlm.nih.gov/34512037/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34512037/
  11. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine:  https://pubmed.ncbi.nlm.nih.gov/34483273/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34483273/ .
  12. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman:  https://pubmed.ncbi.nlm.nih.gov/34513446/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34513446/
  13. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34474550/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34474550/
  14. Reactive arthritis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34033732/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34033732/ .
  15. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants:  https://pubmed.ncbi.nlm.nih.gov/33858208/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33858208/
  16. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab:  https://pubmed.ncbi.nlm.nih.gov/34015240/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34015240/
  17. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34482558/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34482558/
  18. COVID-19 mRNA vaccine causing CNS inflammation: a case series:  https://pubmed.ncbi.nlm.nih.gov/34480607/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34480607/
  19. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19:  https://pubmed.ncbi.nlm.nih.gov/34462647/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34462647/
  20. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/34325334/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34325334/
  21. Tolosa-Hunt syndrome occurring after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34513398/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34513398/
  22. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca):  https://pubmed.ncbi.nlm.nih.gov/34362727/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34362727/
  23. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson):  https://pubmed.ncbi.nlm.nih.gov/34469919/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34469919/ .
  24. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report:  https://pubmed.ncbi.nlm.nih.gov/34516272/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34516272/ .
  25. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report:  https://pubmed.ncbi.nlm.nih.gov/34512961/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34512961/
  26. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34077949/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34077949/
  27. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca):  https://pubmed.ncbi.nlm.nih.gov/34171435/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34171435/
  28. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report:  https://pubmed.ncbi.nlm.nih.gov/34447349/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34447349/
  29. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S:  https://pubmed.ncbi.nlm.nih.gov/34514078/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34514078/
  30. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19:  https://pubmed.ncbi.nlm.nih.gov/34406660/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34406660/ .
  31. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34509658/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34509658/
  1. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34196469/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34196469/ .
  2. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases:  https://pubmed.ncbi.nlm.nih.gov/34350668/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34350668/
  3. Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34436620/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34436620/
  4. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography:  https://pubmed.ncbi.nlm.nih.gov/34116295/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34116295/ .
  5. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems:  https://pubmed.ncbi.nlm.nih.gov/34509271/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34509271/ .
  6. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34462996/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34462996/
  7. Immune thrombocytopenia after vaccination during the COVID-19 pandemic:  https://pubmed.ncbi.nlm.nih.gov/34435486/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34435486/
  8. COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries:  https://pubmed.ncbi.nlm.nih.gov/34435142/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34435142/
  9. Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34429981/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34429981/
  10. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases:  https://pubmed.ncbi.nlm.nih.gov/34427024/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34427024/
  11. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34510014/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34510014/ .
  12. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature:  https://pubmed.ncbi.nlm.nih.gov/34236711/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34236711/
  13. Vaccine-induced thrombocytopenia with severe headache:  https://pubmed.ncbi.nlm.nih.gov/34525282/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34525282/
  14. Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34515024/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34515024/
  15. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34435250/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34435250/ .
  16. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature:  https://pubmed.ncbi.nlm.nih.gov/34363637/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34363637/
  17. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2:  https://www.sciencedirect.com/science/article/pii/S2214250921002018" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2214250921002018
  18. Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination:  https://casereports.bmj.com/content/14/5/e242220.abstract" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://casereports.bmj.com/content/14/5/e242220.abstract .
  19. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34155844/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34155844/
  20. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/ .
  21. Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine:  https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext .
  22. Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/ .
  23. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination:  https://casereports.bmj.com/content/14/7/e242678.full?int_source=trendmd&int_me" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://casereports.bmj.com/content/14/7/e242678.full?int_source=trendmd&int_me dium=cpc&int_campaign=usage-042019
  24. Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination:  https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-a" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-a nd-complement-mediated-hematologic?utm_source=TrendMD&utm_medium=cpc &utm_campaign=Blood_Advances_TrendMD_1.
  25. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results:  https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794?int_source=t" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794?int_source=t rendmd&int_medium=cpc&int_campaign=usage-042019
  26. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria:  https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-i" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-i nduce-severe-hemolysis-in
  27. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany:  https://pubmed.ncbi.nlm.nih.gov/34288044/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34288044/ .
  28. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management:  https://pubmed.ncbi.nlm.nih.gov/34327553/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34327553/ .
  29. Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33878469/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33878469/ .
  1. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom:  https://pubmed.ncbi.nlm.nih.gov/33857630/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33857630/ .
  2. Cerebral venous thrombosis induced by SARS-CoV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34090750/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34090750/ .
  3. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34312301/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34312301/ .
  4. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34333995/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34333995/
  5. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34455073/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34455073/
  6. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34111775/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34111775/ .
  7. Cerebral venous thrombosis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34045111/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34045111/
  8. Lethal cerebral venous sinus thrombosis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33983464/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33983464/
  9. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34116145/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34116145/

Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine:  https://pubmed.ncbi.nlm.nih.gov/34286453/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34286453/ .

  1. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental:  https://pubmed.ncbi.nlm.nih.gov/34478433/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34478433/
  2. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI:  https://pubmed.ncbi.nlm.nih.gov/34244448/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34244448/
  3. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S:  https://pubmed.ncbi.nlm.nih.gov/34226070/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34226070/
  4. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19:  https://pubmed.ncbi.nlm.nih.gov/33845870/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33845870/ .
  5. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34101024/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34101024/ .
  6. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series:  https://pubmed.ncbi.nlm.nih.gov/34393988/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34393988/ .
  7. Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome:  https://pubmed.ncbi.nlm.nih.gov/34407607/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34407607/ .
  8. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study:  https://pubmed.ncbi.nlm.nih.gov/34313952/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34313952/
  9. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST):  https://pubmed.ncbi.nlm.nih.gov/34092166/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34092166/
  10. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency:  https://pubmed.ncbi.nlm.nih.gov/34293217/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34293217/
  11. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination:  https://pubmed.ncbi.nlm.nih.gov/34274191/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34274191/
  12. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation:  https://pubmed.ncbi.nlm.nih.gov/34186376/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34186376/
  13. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study:  https://pubmed.ncbi.nlm.nih.gov/33952445/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33952445/
  14. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34129181/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34129181/
  15. U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021:  https://pubmed.ncbi.nlm.nih.gov/33929487/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33929487/ .
  16. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34341358/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34341358/
  1. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy:  https://pubmed.ncbi.nlm.nih.gov/34175640/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34175640/
  2. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations:  https://pubmed.ncbi.nlm.nih.gov/34159588/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34159588/ .
  3. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca):  https://pubmed.ncbi.nlm.nih.gov/34402666/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402666/
  4. Autoimmunity roots of thrombotic events after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34508917/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34508917/
  5. Cerebral venous sinus thrombosis after vaccination: the UK experience:  https://pubmed.ncbi.nlm.nih.gov/34370974/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34370974/
  6. Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report:  https://pubmed.ncbi.nlm.nih.gov/34373991/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34373991/
  7. Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34490632/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34490632/
  8. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33909350/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33909350/

Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine:  https://pubmed.ncbi.nlm.nih.gov/33981305/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33981305/ .

  1. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:.  https://pubmed.ncbi.nlm.nih.gov/34272622/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34272622/
  2. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:.  https://pubmed.ncbi.nlm.nih.gov/33877737/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33877737/
  3. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34254476/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34254476/
  4. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland:  https://pubmed.ncbi.nlm.nih.gov/34108714/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34108714/

ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34483267/ .




-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:41pm
  1. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34261635/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34261635/
  2. Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT:  https://pubmed.ncbi.nlm.nih.gov/34202817/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34202817/
  3. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report:  https://pubmed.ncbi.nlm.nih.gov/34273119/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34273119/
  4. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19:  https://pubmed.ncbi.nlm.nih.gov/34463066/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34463066/
  5. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/34276917/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34276917/

Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34237213/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34237213/ .

  1. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT):  https://pubmed.ncbi.nlm.nih.gov/34268278/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34268278/ .
  2. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/33990339/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33990339/ .
  3. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study:  https://pubmed.ncbi.nlm.nih.gov/34479760/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34479760/ .

Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of hemorrhage and hematoma after minor oral surgery:  https://pubmed.ncbi.nlm.nih.gov/34314875/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34314875/ .

  1. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34384129/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34384129/
  2. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels:  https://pubmed.ncbi.nlm.nih.gov/34382387/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34382387/
  1. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?:  https://pubmed.ncbi.nlm.nih.gov/34416184/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34416184/ .
  2. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman:  https://pubmed.ncbi.nlm.nih.gov/34261297/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34261297/
  3. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34261296/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34261296/
  4. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2:  https://pubmed.ncbi.nlm.nih.gov/34250318/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34250318/ .
  5. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34059191/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34059191/
  6. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34189756/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34189756/
  7. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34331506/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34331506/
  8. Vaccine-induced thrombocytopenia with severe headache:  https://pubmed.ncbi.nlm.nih.gov/34525282/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34525282/
  9. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database:  https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
  10. COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis:  https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09 .
  11. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine:  https://onlinelibrary.wiley.com/doi/10.1111/trf.16672" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://onlinelibrary.wiley.com/doi/10.1111/trf.16672
  12. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model:  https://t.co/j0IEM8cMXI" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://t.co/j0IEM8cMXI
  13. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics:  https://pubmed.ncbi.nlm.nih.gov/34601006/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34601006/
  14. This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”:  https://www.nejm.org/doi/full/10.1056/NEJMoa2110475?query=featured_home" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/full/10.1056/NEJMoa2110475?query=featured_home
  15. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report:  https://www.sciencedirect.com/science/article/pii/S1201971221007797" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S1201971221007797
  16. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database:  https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1 .
  17. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed:  https://www.sciencedirect.com/science/article/pii/S0168827821020936" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0168827821020936
  18. Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines:  https://www.nature.com/articles/s41421-021-00329-3" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nature.com/articles/s41421-021-00329-3
  19. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
  20. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution:  https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
  21. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome: https://www.science.org/doi/10.1126/sciadv.abl8213" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.science.org/doi/10.1126/sciadv.abl8213
  22. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.:  https://pubmed.ncbi.nlm.nih.gov/34626338/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34626338/
  23. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination:  https://europepmc.org/article/PPR/PPR304469" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://europepmc.org/article/PPR/PPR304469 435.
  24. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34731555/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34731555/
  25. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations:  https://pubmed.ncbi.nlm.nih.gov/34159588/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34159588/
  26. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34461442/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34461442/
  1. Spectrum of neurological complications after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34719776/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34719776/ .
  2. Cerebral venous sinus thrombosis after vaccination: the UK experience:  https://pubmed.ncbi.nlm.nih.gov/34370974/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34370974/
  3. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34373413/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34373413/
  4. Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34598301/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34598301/
  5. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34620638/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34620638/
  6. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient:  https://pubmed.ncbi.nlm.nih.gov/34650896/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34650896/
  7. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34625447/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34625447/
  8. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide:  https://pubmed.ncbi.nlm.nih.gov/34696248/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34696248/
  9. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series:  https://pubmed.ncbi.nlm.nih.gov/34548920/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34548920/
  10. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE):  https://pubmed.ncbi.nlm.nih.gov/34672380/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34672380/ .
  11. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34556531/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34556531/ .
  12. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34535076/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34535076/ .
  13. Clinical features of vaccine-induced thrombocytopenia and immune thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34379914/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34379914/ .
  14. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score:  https://pubmed.ncbi.nlm.nih.gov/34545400/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34545400/
  15. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34035134/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34035134/
  16. In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines:  https://pubmed.ncbi.nlm.nih.gov/34688190/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34688190/
  17. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases:  https://pubmed.ncbi.nlm.nih.gov/34782400/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34782400/
  18. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data:  https://pubmed.ncbi.nlm.nih.gov/34710832/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34710832/
  19. Cerebral venous thrombosis developing after vaccination.

a. COVID-19: VITT, VATT, TTS and more:  https://pubmed.ncbi.nlm.nih.gov/34695859/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34695859/

Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases:  https://pubmed.ncbi.nlm.nih.gov/34453762/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34453762/ .

  1. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech:  https://pubmed.ncbi.nlm.nih.gov/34660652/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34660652/ .
  2. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy:  https://pubmed.ncbi.nlm.nih.gov/34644642/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34644642/
  3. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital:  https://pubmed.ncbi.nlm.nih.gov/34694650/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34694650/
  4. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34726934/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34726934/
  5. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy:  https://pubmed.ncbi.nlm.nih.gov/34835237/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34835237/
  6. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman:  https://pubmed.ncbi.nlm.nih.gov/34261297/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34261297/

Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34724036/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34724036/ .

  1. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA:  https://pubmed.ncbi.nlm.nih.gov/34839563/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34839563/
  1. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34783932/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34783932/ .

COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation:  https://pubmed.ncbi.nlm.nih.gov/34624910/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34624910/

  1. Inflammatory myositis after vaccination with ChAdOx1:  https://pubmed.ncbi.nlm.nih.gov/34585145/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34585145/

Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT):  https://pubmed.ncbi.nlm.nih.gov/34580132/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34580132/ .

  1. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital:  https://pubmed.ncbi.nlm.nih.gov/34535492/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34535492/
  2. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series:  https://pubmed.ncbi.nlm.nih.gov/34527501/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34527501/
  3. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60%.

risk-benefit analysis for people <60 years in Australia:  https://pubmed.ncbi.nlm.nih.gov/34272095/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34272095/

  1. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia:  https://pubmed.ncbi.nlm.nih.gov/34756770/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34756770/
  2. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine:  https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
  3. Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34781321/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34781321/
  4. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines:  https://pubmed.ncbi.nlm.nih.gov/34062319/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34062319/
  5. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India:  https://pubmed.ncbi.nlm.nih.gov/34706921/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34706921/
  6. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis:  https://pubmed.ncbi.nlm.nih.gov/34698582/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34698582/ .
  7. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34751013/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34751013/ .
  8. Acute transverse myelitis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34684047/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34684047/ .
  9. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34541935/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34541935/
  10. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report:  https://pubmed.ncbi.nlm.nih.gov/34273119/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34273119/
  11. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management:  https://pubmed.ncbi.nlm.nih.gov/34327553/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34327553/ .
  12. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33877737/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33877737/
  13. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34646685/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34646685/
  14. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34242687/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34242687/ .
  15. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34609603/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34609603/
  16. Case report: Pityriasis rosea-like rash after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34557507/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34557507/
  17. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34641797/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34641797/ .
  18. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222:  https://pubmed.ncbi.nlm.nih.gov/34812326/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34812326/ .
  19. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):  https://pubmed.ncbi.nlm.nih.gov/34006408/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34006408/
  20. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?:  https://pubmed.ncbi.nlm.nih.gov/34416184/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34416184/
  1. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development:  https://pubmed.ncbi.nlm.nih.gov/34664303/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34664303/ .

Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34649281/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34649281/ .

  1. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34420249/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34420249/

Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis:  https://pubmed.ncbi.nlm.nih.gov/34610990/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34610990/ .

  1. Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman:  https://pubmed.ncbi.nlm.nih.gov/34590397/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34590397/
  2. Sudden sensorineural hearing loss after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34670143/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34670143/ .

Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34819146/ .




-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:42pm
  1. Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination:  https://pubmed.ncbi.nlm.nih.gov/34581453/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34581453/
  2. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy:  https://pubmed.ncbi.nlm.nih.gov/34741583/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34741583/
  3. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report:  https://pubmed.ncbi.nlm.nih.gov/34631069/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34631069/
  4. Thrombosis after COVID-19 vaccination: possible link to ACE pathways:  https://pubmed.ncbi.nlm.nih.gov/34479129/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34479129/
  5. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34331506/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34331506/
  6. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant):  https://pubmed.ncbi.nlm.nih.gov/34546608/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34546608/
  7. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34546343/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34546343/
  8. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34849183/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34849183/
  9. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34853744/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34853744/ .
  10. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222):  https://pubmed.ncbi.nlm.nih.gov/34751429/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34751429/ .
  11. Ocular adverse events following COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34559576/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34559576/
  12. Depression after ChAdOx1-S / nCoV-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34608345/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34608345/ .
  13. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34384129/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34384129/ .
  14. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients:  https://pubmed.ncbi.nlm.nih.gov/34755433/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34755433/
  15. Major artery thrombosis and vaccination against ChAdOx1 nCov-19:  https://pubmed.ncbi.nlm.nih.gov/34839830/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34839830/
  16. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings:  https://pubmed.ncbi.nlm.nih.gov/34667486/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34667486/
  17. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality:  https://pubmed.ncbi.nlm.nih.gov/34726187/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34726187/ .
  18. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34781027/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34781027/
  19. Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination:  https://pubmed.ncbi.nlm.nih.gov/34595694/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34595694/
  20. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers:  https://pubmed.ncbi.nlm.nih.gov/34661934/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34661934/
  21. Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34788138/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34788138/
  22. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34753210/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34753210/ .
  1. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature:  https://pubmed.ncbi.nlm.nih.gov/34653943/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34653943/ .
  2. Relapse of immune thrombocytopenia after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34591991/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34591991/
  3. Thrombosis in pre- and post-vaccination phase of COVID-19;  https://pubmed.ncbi.nlm.nih.gov/34650382/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34650382/
  4. A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review:  https://pubmed.ncbi.nlm.nih.gov/34769454/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34769454/
  5. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective:  https://pubmed.ncbi.nlm.nih.gov/34786893/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34786893/
  6. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis:  https://pubmed.ncbi.nlm.nih.gov/34833382/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34833382/
  7. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen):  https://pubmed.ncbi.nlm.nih.gov/34670287/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34670287/
  8. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34790811/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34790811/
  9. Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia

Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein:  https://pubmed.ncbi.nlm.nih.gov/34023956/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34023956/ .

  1. Thrombosis formation after COVID-19 vaccination immunologic aspects: review article:  https://pubmed.ncbi.nlm.nih.gov/34629931/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34629931/
  2. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca):  https://pubmed.ncbi.nlm.nih.gov/34402666/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402666/
  3. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature:  https://pubmed.ncbi.nlm.nih.gov/34842783/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34842783/
  4. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature:  https://pubmed.ncbi.nlm.nih.gov/34630307/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34630307/
  5. Fatal cerebral venous sinus thrombosis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33983464/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33983464/
  6. Autoimmune roots of thrombotic events after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34508917/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34508917/ .
  7. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19:  https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext .
  8. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33962903/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33962903/ .
  9. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2:  https://pubmed.ncbi.nlm.nih.gov/34796065/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34796065/ .
  10. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors:  https://pubmed.ncbi.nlm.nih.gov/34579248/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34579248/
  11. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34843991/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34843991/
  12. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2):  https://pubmed.ncbi.nlm.nih.gov/34595867/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34595867/
  13. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech):  https://pubmed.ncbi.nlm.nih.gov/34820240/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34820240/
  14. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors:  https://pubmed.ncbi.nlm.nih.gov/33851389/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33851389/
  15. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S:  https://pubmed.ncbi.nlm.nih.gov/33980419/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33980419/
  16. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines:  https://pubmed.ncbi.nlm.nih.gov/34264151/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34264151/
  17. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen:  https://pubmed.ncbi.nlm.nih.gov/34734086/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34734086/
  18. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease:  https://pubmed.ncbi.nlm.nih.gov/34755555/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34755555/
  19. Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome:  https://pubmed.ncbi.nlm.nih.gov/34407607/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34407607/
  1. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34264514/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34264514/ .
  2. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19):  https://pubmed.ncbi.nlm.nih.gov/34840204/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34840204/
  3. Neurological side effects of SARS-CoV-2 vaccines:  https://pubmed.ncbi.nlm.nih.gov/34750810/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34750810/
  4. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways:  https://pubmed.ncbi.nlm.nih.gov/34639132/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34639132/
  5. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up:  https://pubmed.ncbi.nlm.nih.gov/34804412/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34804412/
  6. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report:  https://pubmed.ncbi.nlm.nih.gov/34571653/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34571653/ .
  7. Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A:  https://pubmed.ncbi.nlm.nih.gov/34835275/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34835275/ .
  8. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: xhttps://pubmed.ncbi.nlm.nih.gov/34659839/.
  9. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series:  https://pubmed.ncbi.nlm.nih.gov/34668274/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34668274/ .
  10. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34549821/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34549821/
  11. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant):  https://pubmed.ncbi.nlm.nih.gov/34528522/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34528522/
  12. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34568726/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34568726/
  13. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination:  https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644 5179.
  14. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate:  https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
  15. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types:  https://www.mdpi.com/2075-4426/11/11/1106" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.mdpi.com/2075-4426/11/11/1106
  16. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study:  https://pubmed.ncbi.nlm.nih.gov/34402230/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402230/
  17. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients:  https://pubmed.ncbi.nlm.nih.gov/34696294/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34696294/
  18. Myocarditis Following mRNA COVID-19 Vaccine:  https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
  19. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel:  https://pubmed.ncbi.nlm.nih.gov/34614328/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34614328/ .

Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination:  https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext

  1. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines:  https://pubmed.ncbi.nlm.nih.gov/34277198/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34277198/
  2. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings:  https://pubmed.ncbi.nlm.nih.gov/34246586/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34246586/
  3. Hypersensitivity Myocarditis and COVID-19 Vaccines:  https://pubmed.ncbi.nlm.nih.gov/34856634/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34856634/ .
  4. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?:  https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/f" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/f ulltext.
  5. Acute myocardial infarction and myocarditis after COVID-19 vaccination:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/#" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/# ffn_sectitle.
  6. Myocarditis after Covid-19 vaccination in a large healthcare organization:  https://www.nejm.org/doi/10.1056/NEJMoa2110737?url_ver=Z39.88-2003&rfr_id=" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.nejm.org/doi/10.1056/NEJMoa2110737?url_ver=Z39.88-2003&rfr_id= ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
  7. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children:  https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
  8. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults:  https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
  1. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:.  https://pubmed.ncbi.nlm.nih.gov/34756746/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34756746/
  1. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/#" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/# ffn_sectitle.
  2. Myocarditis after COVID-19 mRNA vaccines:  https://pubmed.ncbi.nlm.nih.gov/34546329/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34546329/ .
  3. Patients with acute myocarditis after COVID-19 mRNA vaccination:.  https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602 .
  4. Myocarditis after COVID-19 vaccination: a case series:  https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub .
  5. Myocarditis associated with COVID-19 vaccination in adolescents:  https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357/COVID-1" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357/COVID-1 9-Vaccination-Associated-Myocarditis-in.
  6. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:.  https://pubmed.ncbi.nlm.nih.gov/34704459/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34704459/
  7. myocarditis after COVID-19 vaccination: magnetic resonance imaging study:  https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6 421640.
  8. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/#ffn_sectitle" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/#ffn_sectitle .
  9. Myocarditis after COVID-19 vaccination:  https://www.sciencedirect.com/science/article/pii/S2352906721001603?via%3Dihub" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S2352906721001603?via%3Dihub .
  10. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy:  https://pubmed.ncbi.nlm.nih.gov/34712717/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34712717/ .
  11. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:  https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administratio" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administratio n-bnt162b2-S188558572100133X.
  12. Myocarditis associated with COVID-19 mRNA vaccination:.  https://pubs.rsna.org/doi/10.1148/radiol.2021211430?url_ver=Z39.88-2003&rfr_id=" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubs.rsna.org/doi/10.1148/radiol.2021211430?url_ver=Z39.88-2003&rfr_id= ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.
  13. Acute myocarditis after COVID-19 vaccination: a case report:  https://www.sciencedirect.com/science/article/pii/S0248866321007098?via%3Dihu" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S0248866321007098?via%3Dihu b.
  14. Acute myopericarditis after COVID-19 vaccination in adolescents:.  https://pubmed.ncbi.nlm.nih.gov/34589238/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34589238/ .
  15. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination:  https://academic.oup.com/jpids/article/10/10/962/6329543" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/jpids/article/10/10/962/6329543 .
  16. Acute myocarditis associated with anti-COVID-19 vaccination:  https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196 .
  17. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:.  https://pubmed.ncbi.nlm.nih.gov/34428917/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34428917/ .
  18. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:.  https://pubmed.ncbi.nlm.nih.gov/34088762/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34088762/ .
  19. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:.  https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/64" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/64 42104.
  20. COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis:  https://www.mdpi.com/2036-7503/13/3/61" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.mdpi.com/2036-7503/13/3/61 .

Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA:  https://pubmed.ncbi.nlm.nih.gov/34402228/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402228/ 600.



-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:44pm
  1. Myocarditis temporally associated with COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34133885/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34133885/
  2. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database:  https://pubmed.ncbi.nlm.nih.gov/34219532/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34219532/
  3. Acute myocarditis associated with COVID-19 vaccination: report of a case:  https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/#" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/# ffn_sectitle
  4. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series:  https://pubmed.ncbi.nlm.nih.gov/34840235/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34840235/ .
  5. Myocarditis in the setting of a recent COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34712497/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34712497/ .
  6. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases:  https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext .
  7. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19:  https://pubmed.ncbi.nlm.nih.gov/34568726/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34568726/
  8. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination:  https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179
  1. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination:  https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408 .
  2. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types:  https://www.mdpi.com/2075-4426/11/11/1106" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.mdpi.com/2075-4426/11/11/1106
  3. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study:  https://pubmed.ncbi.nlm.nih.gov/34402230/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34402230/
  4. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients:  https://pubmed.ncbi.nlm.nih.gov/34696294/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34696294/
  5. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34615534/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34615534/
  6. Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34352418/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34352418/
  7. Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19;  https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.long" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.long
  8. CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count:  https://pubmed.ncbi.nlm.nih.gov/34632750/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34632750/
  9. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia:  https://haematologica.org/article/view/haematol.2021.279075" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://haematologica.org/article/view/haematol.2021.279075
  10. COVID-19 vaccine-induced thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34802488/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34802488/ .
  11. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis:  https://pubmed.ncbi.nlm.nih.gov/34887867/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34887867/ .
  12. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34863404/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34863404/ .
  13. Vaccine-induced cerebral venous thrombosis and thrombocytopenia.

Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience:  https://www.sciencedirect.com/science/article/pii/S235255682100093X?via%3Dihu" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.sciencedirect.com/science/article/pii/S235255682100093X?via%3Dihu b

  1. Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34876440/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34876440/
  2. Deep venous thrombosis more than two weeks after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33928773/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33928773/
  3. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome:  https://pubmed.ncbi.nlm.nih.gov/34880826/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34880826/
  4. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia:  https://pubmed.ncbi.nlm.nih.gov/34587242/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34587242/
  5. Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome:  https://pubmed.ncbi.nlm.nih.gov/34868465/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34868465/
  6. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT):  https://pubmed.ncbi.nlm.nih.gov/34097311/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34097311/
  7. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors:  https://pubmed.ncbi.nlm.nih.gov/34820232/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34820232/ .
  8. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy:  https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
  9. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series:  https://pubmed.ncbi.nlm.nih.gov/34579636/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34579636/
  10. Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient:  https://pubmed.ncbi.nlm.nih.gov/34614491/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34614491/
  11. Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273:  https://pubmed.ncbi.nlm.nih.gov/34790684/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34790684/
  12. Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19):  https://pubmed.ncbi.nlm.nih.gov/33624509/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33624509/ .
  13. Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech):  https://pubmed.ncbi.nlm.nih.gov/34612003/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34612003/
  14. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism:  https://pubmed.ncbi.nlm.nih.gov/34096082/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34096082/

Myocarditis associated with COVID-19 vaccination in three adolescent boys:  https://pubmed.ncbi.nlm.nih.gov/34851078/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34851078/ .

  1. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series:  https://pubmed.ncbi.nlm.nih.gov/34496880/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34496880/
  2. Perimyocarditis after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34866957/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34866957/
  3. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination:  https://pubmed.ncbi.nlm.nih.gov/34849657/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34849657/ .
  4. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings:  https://pubmed.ncbi.nlm.nih.gov/34664804/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34664804/
  5. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older:  https://pubmed.ncbi.nlm.nih.gov/34605853/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34605853/
  6. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male:  https://pubmed.ncbi.nlm.nih.gov/34166671/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34166671/
  7. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination:  https://pubmed.ncbi.nlm.nih.gov/34744118/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34744118/
  8. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male:  https://pubmed.ncbi.nlm.nih.gov/34334935/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34334935/ .
  9. 68 Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34746968/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34746968/
  10. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”:  https://pubmed.ncbi.nlm.nih.gov/34333695/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34333695/ .
  11. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34180390/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34180390/

Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military:  https://pubmed.ncbi.nlm.nih.gov/34185045/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34185045/

  1. Myocarditis after BNT162b2 vaccination in a healthy male:  https://pubmed.ncbi.nlm.nih.gov/34229940/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34229940/
  2. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report:  https://pubmed.ncbi.nlm.nih.gov/34133825/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34133825/
  3. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination:  https://pubmed.ncbi.nlm.nih.gov/34308326/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34308326/ .
  4. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna:  https://pubmed.ncbi.nlm.nih.gov/34866106/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34866106/
  5. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report:  https://pubmed.ncbi.nlm.nih.gov/34487236/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34487236/
  6. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273:  https://pubmed.ncbi.nlm.nih.gov/34848416/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34848416/
  7. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male:  https://pubmed.ncbi.nlm.nih.gov/34636504/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34636504/
  8. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection:  https://pubmed.ncbi.nlm.nih.gov/34367386/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34367386/
  9. Acute myocarditis in a young adult two days after vaccination with Pfizer:  https://pubmed.ncbi.nlm.nih.gov/34709227/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34709227/
  10. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation:  https://pubmed.ncbi.nlm.nih.gov/34778411/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34778411/
  11. Acute myocarditis after 2019 coronavirus disease vaccination:  https://pubmed.ncbi.nlm.nih.gov/34734821/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34734821/
  12. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2:  https://pubmed.ncbi.nlm.nih.gov/34246585/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34246585/
  13. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents:  https://pubmed.ncbi.nlm.nih.gov/34228985/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34228985/
  14. Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection:  https://pubmed.ncbi.nlm.nih.gov/34852213/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34852213/
  15. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease:  https://pubmed.ncbi.nlm.nih.gov/34866122/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34866122/
  16. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34601566/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34601566/
  1. Myocarditis following COVID-19 vaccination: MRI study:  https://pubmed.ncbi.nlm.nih.gov/34739045/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34739045/ .
  2. Acute myocarditis after COVID-19 vaccination: case report:  https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e dit#.
  3. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children:  https://pubmed.ncbi.nlm.nih.gov/34374740/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34374740/
  4. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults:  https://pubmed.ncbi.nlm.nih.gov/34865500/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34865500/
  5. Myocarditis following vaccination with Covid-19 in a large healthcare organization:  https://pubmed.ncbi.nlm.nih.gov/34614329/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34614329/
  6. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link:  https://pubmed.ncbi.nlm.nih.gov/34560365/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34560365/
  7. COVID-19, Guillain-Barré and vaccineA dangerous mix:  https://pubmed.ncbi.nlm.nih.gov/34108736/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34108736/ .
  8. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases:  https://pubmed.ncbi.nlm.nih.gov/34796417/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34796417/ .
  9. Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine:  https://link.springer.com/article/10.1007%2Fs10072-021-05523-5" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://link.springer.com/article/10.1007%2Fs10072-021-05523-5 .
  10. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy:  https://onlinelibrary.wiley.com/doi/10.1002/ana.26258" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://onlinelibrary.wiley.com/doi/10.1002/ana.26258 .
  11. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021:  https://jamanetwork.com/journals/jama/fullarticle/2785009" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jama/fullarticle/2785009
  12. A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34567447/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34567447/
  13. Guillain-Barré syndrome associated with COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34648420/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34648420/ .
  14. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine:

https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708

  1. Guillain-Barre syndrome after COVID-19 vaccination in an adolescent:  https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext .

Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34114256/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34114256/ .

  1. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34767184/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34767184/ .
  2. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients:  https://pubmed.ncbi.nlm.nih.gov/34644738/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34644738/ .
  3. Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients:  https://pubmed.ncbi.nlm.nih.gov/34649856/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34649856/
  4. A rare case of Guillain-Barré syndrome after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34671572/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34671572/
  5. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33758714/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33758714/
  6. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect:  https://pubmed.ncbi.nlm.nih.gov/34484780/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34484780/
  7. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report;  https://pubmed.ncbi.nlm.nih.gov/34779385/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34779385/ .
  8. Miller Fisher syndrome after Pfizer COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34817727/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34817727/ .
  9. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination:  https://pubmed.ncbi.nlm.nih.gov/34789193/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34789193/ .
  10. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34261746/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34261746/
  11. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report:  https://pubmed.ncbi.nlm.nih.gov/34217513/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34217513/ .
  12. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer):  https://pubmed.ncbi.nlm.nih.gov/34871447/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34871447/
  13. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase:  https://pubmed.ncbi.nlm.nih.gov/34579259/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34579259/
  14. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN:  https://pubmed.ncbi.nlm.nih.gov/34370408/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34370408/ .
  15. A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S:  https://pubmed.ncbi.nlm.nih.gov/34703690/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34703690/ .
  16. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome:  https://pubmed.ncbi.nlm.nih.gov/34810163/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34810163/
  1. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines:  https://onlinelibrary.wiley.com/doi/10.1002/ana.26218" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://onlinelibrary.wiley.com/doi/10.1002/ana.26218 .
  2. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature:  https://pubmed.ncbi.nlm.nih.gov/34482455/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34482455/ .


-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:45pm
  1. Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34114269/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34114269/ .
  2. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine:  https://pubmed.ncbi.nlm.nih.gov/34722067/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34722067/
  3. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association:  https://pubmed.ncbi.nlm.nih.gov/33968610/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33968610/
  4. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy:  https://pubmed.ncbi.nlm.nih.gov/34525410/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34525410/
  5. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine:  https://pubmed.ncbi.nlm.nih.gov/34808658/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34808658/
  6. Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination:  https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fullte" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fullte xt.
  7. Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence?:  https://pubmed.ncbi.nlm.nih.gov/34522557/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34522557/
  8. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34763263/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34763263/ .
  9. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report:  https://pubmed.ncbi.nlm.nih.gov/34621891/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34621891/
  10. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection:  https://pubmed.ncbi.nlm.nih.gov/34697502/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34697502/
  11. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy:  https://pubmed.ncbi.nlm.nih.gov/33858693/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33858693/
  12. Acute transverse myelitis following inactivated COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34370410/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34370410/
  13. Acute transverse myelitis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34579245/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34579245/ .
  14. A case of longitudinally extensive transverse myelitis following Covid-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34182207/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34182207/
  15. Post COVID-19 transverse myelitis; a case report with review of the literature:  https://pubmed.ncbi.nlm.nih.gov/34457267/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34457267/ .
  16. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34189662/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34189662/
  17. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273:  https://pubmed.ncbi.nlm.nih.gov/34660149/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34660149/
  18. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/34131771/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34131771/
  19. A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States:  https://pubmed.ncbi.nlm.nih.gov/34635376/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34635376/
  20. Acute pericarditis and cardiac tamponade after vaccination with Covid-19:  https://pubmed.ncbi.nlm.nih.gov/34749492/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34749492/
  21. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines:  https://pubmed.ncbi.nlm.nih.gov/34849667/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34849667/
  22. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34319393/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34319393/
  23. Acute myopericarditis after COVID-19 vaccine in adolescents:  https://pubmed.ncbi.nlm.nih.gov/34589238/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34589238/
  24. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34149145/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34149145/
  25. Case report: symptomatic pericarditis post COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34693198/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34693198/ .
  26. An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient:  https://pubmed.ncbi.nlm.nih.gov/34797392/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34797392/
  27. Lessons of the month 3: Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19):  https://pubmed.ncbi.nlm.nih.gov/34862234/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34862234/
  28. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series:  https://pubmed.ncbi.nlm.nih.gov/34396358/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34396358/ .
  1. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34848426/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34848426/ .
  2. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/33946748/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33946748/
  3. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines:  https://pubmed.ncbi.nlm.nih.gov/34591186/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34591186/
  4. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34352309/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34352309/
  5. Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient:  https://pubmed.ncbi.nlm.nih.gov/34804803/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34804803/ .
  6. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2:  https://pubmed.ncbi.nlm.nih.gov/34077572/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34077572/
  7. Retinal hemorrhage after SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34884407/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34884407/ .
  8. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34859017/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34859017/
  9. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report:  https://pubmed.ncbi.nlm.nih.gov/34783899/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34783899/
  10. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34549178/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34549178/ .
  11. Brain death in a vaccinated patient with COVID-19 infection:  https://pubmed.ncbi.nlm.nih.gov/34656887/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34656887/
  12. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination:  https://pubmed.ncbi.nlm.nih.gov/34236717/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34236717/ .
  13. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34729467/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34729467/ .
  14. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33932458/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33932458/
  15. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction:  https://pubmed.ncbi.nlm.nih.gov/34092400/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34092400/ 742.
  16. Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34754937/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34754937/
  17. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy:  https://pubmed.ncbi.nlm.nih.gov/33771584/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33771584/
  18. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34846583/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34846583/
  19. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis:  https://pubmed.ncbi.nlm.nih.gov/34073536/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34073536/
  20. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study:  https://pubmed.ncbi.nlm.nih.gov/34411532/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34411532/
  21. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval:  https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
  22. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria:  https://pubmed.ncbi.nlm.nih.gov/33851711/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33851711/
  23. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination:  https://pubmed.ncbi.nlm.nih.gov/34675550/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34675550/ .
  24. Anaphylaxis after Modern COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34734159/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34734159/ .
  25. Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34698847/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34698847/
  26. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34020815/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34020815/
  27. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020:  https://pubmed.ncbi.nlm.nih.gov/33641264/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33641264/
  28. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021:  https://pubmed.ncbi.nlm.nih.gov/33641268/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33641268/
  29. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action:  https://pubmed.ncbi.nlm.nih.gov/33834172/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33834172/
  30. Pseudo-anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2:  https://pubmed.ncbi.nlm.nih.gov/34579211/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34579211/
  1. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result:  https://pubmed.ncbi.nlm.nih.gov/34343674/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34343674/
  2. Acute myocardial infarction and myocarditis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34586408/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34586408/
  3. Takotsubo syndrome after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34539938/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34539938/ .

Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis:  https://pubmed.ncbi.nlm.nih.gov/34731486/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34731486/ .

  1. Premature myocardial infarction or side effect of COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33824804/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33824804/
  2. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older:  https://pubmed.ncbi.nlm.nih.gov/34807248/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34807248/
  3. Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34148772/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34148772/
  4. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit:  https://pubmed.ncbi.nlm.nih.gov/34702550/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34702550/
  5. Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®):  https://pubmed.ncbi.nlm.nih.gov/33895650/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33895650/
  6. Deaths associated with recently launched SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34425384/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34425384/
  7. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect:  https://pubmed.ncbi.nlm.nih.gov/34703815/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34703815/ 767.
  8. COVID-19 vaccine-induced urticarial vasculitis:  https://pubmed.ncbi.nlm.nih.gov/34369046/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34369046/ .
  9. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34280507/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34280507/ .
  10. New-onset leukocytoclastic vasculitis after COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34241833/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34241833/
  11. Cutaneous small vessel vasculitis after COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34529877/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34529877/ .
  12. Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33928638/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33928638/
  13. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34836739/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34836739/
  14. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?;  https://pubmed.ncbi.nlm.nih.gov/34495381/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34495381/ .
  15. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine:  https://pubmed.ncbi.nlm.nih.gov/34327795/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34327795/
  16. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34660867/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34660867/ .
  17. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA:  https://pubmed.ncbi.nlm.nih.gov/34659268/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34659268/
  18. Reactivation of IgA vasculitis after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34848431/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34848431/
  19. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34310759/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34310759/ .
  20. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster:  https://pubmed.ncbi.nlm.nih.gov/34720009/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34720009/
  21. A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34518812/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34518812/
  22. Cutaneous vasculitis following COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34611627/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34611627/ .
  23. Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis:  https://pubmed.ncbi.nlm.nih.gov/34705320/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34705320/ .
  24. IgA vasculitis following COVID-19 vaccination in an adult:  https://pubmed.ncbi.nlm.nih.gov/34779011/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34779011/
  25. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34451967/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34451967/
  26. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis:  https://pubmed.ncbi.nlm.nih.gov/33928459/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33928459/
  27. Reactivation of IgA vasculitis after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34250509/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34250509/
  28. Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34292611/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34292611/ .
  29. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report:  https://pubmed.ncbi.nlm.nih.gov/34530771/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34530771/ .
  1. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine:

true association or circumstantial:  https://pubmed.ncbi.nlm.nih.gov/34245294/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34245294/ .

  1. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19):  https://pubmed.ncbi.nlm.nih.gov/34599716/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34599716/ .
  2. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils:  https://pubmed.ncbi.nlm.nih.gov/34115904/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34115904/ .
  3. Henoch-Schönlein purpura occurring after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34247902/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34247902/ .
  4. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report:  https://pubmed.ncbi.nlm.nih.gov/34696186/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34696186/ .
  5. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34237323/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34237323/ .
  6. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA:  https://pubmed.ncbi.nlm.nih.gov/34851795/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34851795/ .
  7. A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34849386/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34849386/
  8. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/34310763/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34310763/
  9. Relapse of microscopic polyangiitis after COVID-19 vaccination: case report:  https://pubmed.ncbi.nlm.nih.gov/34251683/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34251683/ .


-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:46pm
  1. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34557622/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34557622/ .
  2. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases:  https://pubmed.ncbi.nlm.nih.gov/34510694/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34510694/

Leukocytoclastic vasculitis after coronavirus disease vaccination 2019:  https://pubmed.ncbi.nlm.nih.gov/34713472/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34713472/ 803.

  1. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2:  https://pubmed.ncbi.nlm.nih.gov/34819272/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34819272/
  2. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S:  https://pubmed.ncbi.nlm.nih.gov/34337124/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34337124/
  3. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019:  https://pubmed.ncbi.nlm.nih.gov/34535924/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34535924/
  4. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report:  https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/full?fbclid=IwAR3c" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/full?fbclid=IwAR3c kIK1OuR4unrknRvUSuj1LWiTJvvvg-BF4JZZCxv_wQMKZpvIznABN2dE.
  5. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT:  https://pubmed.ncbi.nlm.nih.gov/33591026/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33591026/
  6. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients:  https://pubmed.ncbi.nlm.nih.gov/33625300/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33625300/
  7. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation:  https://pubmed.ncbi.nlm.nih.gov/33774684/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33774684/
  8. Lymphadenopathy after COVID-19 vaccination: review of imaging findings:  https://pubmed.ncbi.nlm.nih.gov/33985872/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33985872/
  9. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34735411/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34735411/
  10. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine:  https://pubmed.ncbi.nlm.nih.gov/34115709/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34115709/ .
  11. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases:  https://pubmed.ncbi.nlm.nih.gov/34257025/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34257025/ .
  12. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review:  https://pubmed.ncbi.nlm.nih.gov/34836672/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34836672/ .
  13. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study:  https://pubmed.ncbi.nlm.nih.gov/34280870/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34280870/
  14. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings:  https://pubmed.ncbi.nlm.nih.gov/34432391/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34432391/
  15. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care:  https://pubmed.ncbi.nlm.nih.gov/34731748/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34731748/
  16. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography:  https://pubmed.ncbi.nlm.nih.gov/34906409/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34906409/
  1. Do you want even more proof? Listed here are 140 references to adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021:  https://pubmed.ncbi.nlm.nih.gov/33706861/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33706861/
  2. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography:  https://pubmed.ncbi.nlm.nih.gov/34116295/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34116295/
  3. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding:  https://pubmed.ncbi.nlm.nih.gov/33661328/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33661328/
  4. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34050949/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34050949/
  5. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women:  https://pubmed.ncbi.nlm.nih.gov/33624520/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33624520/
  6. A case of cervical lymphadenopathy following COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34141500/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34141500/
  7. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report:  https://pubmed.ncbi.nlm.nih.gov/34096896/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34096896/
  8. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database:  https://pubmed.ncbi.nlm.nih.gov/34835256/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34835256/
  9. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties:  https://pubmed.ncbi.nlm.nih.gov/33713605/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33713605/
  10. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up:  https://pubmed.ncbi.nlm.nih.gov/34298342/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34298342/
  11. A systematic review of cases of CNS demyelination following COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34839149/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34839149/
  12. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic:  https://pubmed.ncbi.nlm.nih.gov/33685772/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33685772/
  13. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT:  https://pubmed.ncbi.nlm.nih.gov/34719892/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34719892/
  14. Adenopathy after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33625299/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33625299/ .
  15. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34292295/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34292295/ .
  16. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit:  https://pubmed.ncbi.nlm.nih.gov/33947605/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33947605/ .
  17. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services:  https://pubmed.ncbi.nlm.nih.gov/34526175/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34526175/
  18. Lymphadenopathy associated with the COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33786231/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33786231/
  19. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33625301/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33625301/ .
  20. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34332438/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34332438/ .
  21. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review:  https://pubmed.ncbi.nlm.nih.gov/34342187/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34342187/ .
  22. Massive cervical lymphadenopathy following vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34601889/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34601889/
  23. ANCA glomerulonephritis following Modern COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34081948/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34081948/
  24. Month 1 lessons: extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34507942/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34507942/ .
  25. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca):  https://pubmed.ncbi.nlm.nih.gov/34362727/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34362727/
  26. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation:  https://pubmed.ncbi.nlm.nih.gov/34325221/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34325221/
  27. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma:  https://pubmed.ncbi.nlm.nih.gov/34825530/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34825530/ .
  28. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34000278/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34000278/
  29. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA:  https://pubmed.ncbi.nlm.nih.gov/34655312/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34655312/ .
  30. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34187985/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34187985/ .
  31. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021:  https://pubmed.ncbi.nlm.nih.gov/33706861/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33706861/
  32. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography:  https://pubmed.ncbi.nlm.nih.gov/34116295/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34116295/
  33. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding:  https://pubmed.ncbi.nlm.nih.gov/33661328/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33661328/
  34. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34050949/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34050949/
  35. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women:  https://pubmed.ncbi.nlm.nih.gov/33624520/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33624520/
  36. A case of cervical lymphadenopathy following COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34141500/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34141500/
  37. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report:  https://pubmed.ncbi.nlm.nih.gov/34096896/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34096896/
  38. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database:  https://pubmed.ncbi.nlm.nih.gov/34835256/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34835256/
  39. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties:  https://pubmed.ncbi.nlm.nih.gov/33713605/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33713605/
  40. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up:  https://pubmed.ncbi.nlm.nih.gov/34298342/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34298342/
  41. A systematic review of cases of CNS demyelination following COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34839149/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34839149/
  42. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic:  https://pubmed.ncbi.nlm.nih.gov/33685772/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33685772/
  43. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT:  https://pubmed.ncbi.nlm.nih.gov/34719892/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34719892/
  44. Adenopathy after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33625299/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33625299/ .
  45. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34292295/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34292295/ .
  46. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit:  https://pubmed.ncbi.nlm.nih.gov/33947605/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33947605/ .
  47. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services:  https://pubmed.ncbi.nlm.nih.gov/34526175/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34526175/
  48. Lymphadenopathy associated with the COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/33786231/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33786231/
  49. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/33625301/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/33625301/ .
  50. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34332438/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34332438/ .
  51. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review:  https://pubmed.ncbi.nlm.nih.gov/34342187/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34342187/ .
  52. Massive cervical lymphadenopathy following vaccination with COVID-19:  https://pubmed.ncbi.nlm.nih.gov/34601889/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34601889/
  53. ANCA glomerulonephritis following Modern COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34081948/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34081948/
  54. Month 1 lessons: extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34507942/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34507942/ .
  55. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca):  https://pubmed.ncbi.nlm.nih.gov/34362727/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34362727/
  56. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation:  https://pubmed.ncbi.nlm.nih.gov/34325221/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34325221/
  57. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma:  https://pubmed.ncbi.nlm.nih.gov/34825530/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34825530/ .
  58. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine:  https://pubmed.ncbi.nlm.nih.gov/34000278/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34000278/
  59. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA:  https://pubmed.ncbi.nlm.nih.gov/34655312/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34655312/ .
  60. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination:  https://pubmed.ncbi.nlm.nih.gov/34187985/" rel="nofollow" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://pubmed.ncbi.nlm.nih.gov/34187985/ .


-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:48pm

Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34416319

Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34092429

Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34025885

Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34586408

Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34756746

Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34432976

Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34754400

Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/34281357" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34281357

Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34835284

Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/34366403" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34366403

Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34564344

Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34617315

Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. https://www.ncbi.nlm.nih.gov/pubmed/34333695" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34333695

Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34833382

Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34704459

Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34664804

Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34860360

Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34849657

Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34933012

Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34547487

Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. https://www.ncbi.nlm.nih.gov/pubmed/34339728" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34339728

Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34356586

Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34219532

Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34246585

Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34492161

Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34844930

Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. https://www.ncbi.nlm.nih.gov/pubmed/34487236" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34487236

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. https://www.ncbi.nlm.nih.gov/pubmed/34551225" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34551225

Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34709227

Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34921468

Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. https://www.ncbi.nlm.nih.gov/pubmed/34824230" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34824230

Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; - https://doi.org/10.1007/s00392-020-01704-y . Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34170372

Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34849667

Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34646267

Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34127481

Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34538306

Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34237049

Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33406694

Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34660088

Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34916217

Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34153517

Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34668687

Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. https://www.ncbi.nlm.nih.gov/pubmed/34348657" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34348657

Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/34351881" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34351881

Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33854395

Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34446426



-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:50pm

Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34808708

Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. https://www.ncbi.nlm.nih.gov/pubmed/34347278" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34347278

In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/34544112https:/www.ncbi.nlm.nih.gov/pubmed/34544112" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/34544112

Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34463755

Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. https://www.ncbi.nlm.nih.gov/pubmed/34931681" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34931681

Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34342500

Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34805376

Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34834983

Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. https://www.ncbi.nlm.nih.gov/pubmed/34389692" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34389692

Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34270752

Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/pubmed/34744118" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34744118

Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34568540

Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/34447639" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34447639

Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34185046

Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. https://www.ncbi.nlm.nih.gov/pubmed/34402228" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34402228

King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34396358

Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34477808

Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. https://www.ncbi.nlm.nih.gov/pubmed/33898162" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33898162

Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. https://www.ncbi.nlm.nih.gov/pubmed/33643776" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33643776

Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. https://www.ncbi.nlm.nih.gov/pubmed/34952008" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34952008

Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34642628

Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34540594

Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. https://www.ncbi.nlm.nih.gov/pubmed/34378087" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34378087

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. https://www.ncbi.nlm.nih.gov/pubmed/34127854" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34127854

Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34393110

Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34463770

Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33606296

Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34535317" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34535317

Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. https://www.ncbi.nlm.nih.gov/pubmed/33888900" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33888900

Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34834458

Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34778411

Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057. https://www.ncbi.nlm.nih.gov/pubmed/34332972" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34332972

Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34375696

Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093/cid/ciab954. https://www.ncbi.nlm.nih.gov/pubmed/34791081" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34791081

Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34676123

Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34398511

Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33316478

McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34133825

Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. https://www.ncbi.nlm.nih.gov/pubmed/34614328" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34614328

Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34166671

Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-3. https://www.ncbi.nlm.nih.gov/pubmed/34737312" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34737312

Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-20. https://www.ncbi.nlm.nih.gov/pubmed/33526560" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33526560

Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0. https://www.ncbi.nlm.nih.gov/pubmed/34930152" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34930152

Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34185045

Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. https://www.ncbi.nlm.nih.gov/pubmed/34840235" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34840235

Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34876937

Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34089859

Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34889875

Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4. https://www.ncbi.nlm.nih.gov/pubmed/34320609" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34320609

Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232. https://www.ncbi.nlm.nih.gov/pubmed/34402230" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34402230

Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34180390

Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. https://www.ncbi.nlm.nih.gov/pubmed/34496880" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34496880

Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-0. https://www.ncbi.nlm.nih.gov/pubmed/34907393" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34907393

Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34367386

Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926. https://www.ncbi.nlm.nih.gov/pubmed/34734240" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34734240

Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9. https://www.ncbi.nlm.nih.gov/pubmed/34738774" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34738774

Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34695229

Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34233234

Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34934954

Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. https://www.ncbi.nlm.nih.gov/pubmed/34228985" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34228985

Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. https://www.ncbi.nlm.nih.gov/pubmed/34591186" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34591186

Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5. https://www.ncbi.nlm.nih.gov/pubmed/34241676" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34241676

Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34945172

Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34707602

Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. https://www.ncbi.nlm.nih.gov/pubmed/33956784" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33956784

Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759/cureus.16383. https://www.ncbi.nlm.nih.gov/pubmed/34408937" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34408937

Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34739045

Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34605853

Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34341797

Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1. https://www.ncbi.nlm.nih.gov/pubmed/34764489" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34764489

Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34077949

Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34911654

Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34282971

Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34420869

Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34514306

Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/pubmed/34955479" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34955479

Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. https://www.ncbi.nlm.nih.gov/pubmed/33444297" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33444297

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056/NEJMoa2107058. https://www.ncbi.nlm.nih.gov/pubmed/34192428" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34192428

Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34866957



-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:52pm

Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/34865500" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34865500

Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34311983

Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34904134

Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576. https://www.ncbi.nlm.nih.gov/pubmed/34277198" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34277198

Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34731877

Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34533570

Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34229940

Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34336774

Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054. https://www.ncbi.nlm.nih.gov/pubmed/34006408" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34006408

Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. https://www.ncbi.nlm.nih.gov/pubmed/34614329" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/34614329

Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338. https://www.ncbi.nlm.nih.gov/pubmed/33262177" style="box-sizing: border-box; transition: color 0.1s ease-in-out 0s, background-color 0.1s ease-in-out 0s; color: rgb(36, 119, 141); text-decoration: none; margin-bottom: 0px; - https://www.ncbi.nlm.nih.gov/pubmed/33262177



-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.

Posted By: A-I
Date Posted: January 07 2022 at 1:54pm

Questions and concerns, yeah I got a few based on science. And rightly so.



-------------
"Facts don't care about your feelings" I'M A UNVAXXED DEVIL so kiss my rebel ass.


Print Page | Close Window